TransCon IL-2 beta/gamma is under clinical development by Ascendis Pharma and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TransCon IL-2 beta/gamma’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TransCon IL-2 beta/gamma overview
Recombinant Protein is under development for the treatment of advanced, recurrent, or metastatic solid tumor including melanoma, cervical cancer, head and neck cancer squamous cell carcinoma, renal cell carcinoma, metastatic colorectal cancer, colon cancer and other human papilloma virus associated cancers. The drug candidate comprises of a protein conjugated to a carrier via a TransCon hGH linker and administered through intravenous route. It acts by targeting interleukin-2 receptor subunit beta and gamma. It is being developed based on the TransCon technology platform.
Ascendis Pharma overview
Ascendis Pharma is a biopharmaceutical company that focuses on developing drugs for endocrinology and oncology indications. It is investigating TransCon hGH, a long-acting human growth hormone prodrug targeting GHD (growth hormone deficiency); TransCon PTH drug to treat hypoparathyroidism by restoring physiologic levels of PTH (parathyroid hormone); and TransCon CNP, a CNP (C-type natriuretic peptide) drug against achondroplasia (ACH). It is also evaluating TransCon TLR (toll-like receptor) 7/8 agonist, and TransCon IL-2 ß/?, an interleukin-2 variant that activates the IL-2 receptor beta/gamma (IL-2Rß/?) for the treatment of cancer. Ascendis Pharma utilizes its proprietary TransCon technology platform to develop its drugs. The company operates in the US, Germany and Denmark. Ascendis Pharma is headquartered in Hellerup, Denmark.
For a complete picture of TransCon IL-2 beta/gamma’s drug-specific PTSR and LoA scores, buy the report here.